Plant disease control composition and preparation method and application thereof
Through virtual screening and chemical synthesis of target proteins, highly active tryptophan hydrazide or tryptophan amide compounds were developed, which solved the problem of preventing and treating plant fungi and bacterial diseases, provided efficient and low-toxic green pesticides, and achieved the goal of the multi-purpose Effective inhibition of pathogens.
Patent Information
- Application Number
- CN202411000527.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-25
AI Technical Summary
The prior art is difficult to effectively prevent and control plant fungal and bacterial diseases, resulting in a decline in crop yield and quality, and traditional pesticides have toxicity and environmental pollution problems.
Based on the virtual screening and chemical synthesis of target proteins, high-active tryptophan hydrazide or tryptophan amide compounds were developed. Through virtual screening, chemical synthesis, activity determination and other studies, compounds acting on target proteins were synthesized and screened to obtain high-quality Active bactericidal function compound structure.
This compound has a good inhibitory effect on a variety of plant pathogens, provides new efficient, low-toxic and safe green pesticide selection, effectively control plant diseases, and supports the research and development and creation of new pesticides.
Smart Images

Figure CN118546085B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of pharmaceutical chemistry and plant protection, and relates to a plant disease prevention and control composition, a preparation method and application thereof. Background Art
[0002] In recent years, plant fungal and bacterial diseases have seriously affected the yield and quality of crops worldwide, causing a decrease in crop yield and quality, and even huge economic losses. For example, Fusarium graminearum ( Fusarium graminearum ) is a filamentous ascomycete that can cause wheat seedling rot, stem base rot, stalk rot and ear rot, causing at least 10-20% reduction in wheat production in wheat-growing countries every year. Xanthomonas oryzae pv. oryzae ) is a rod-shaped Gram-negative bacterium that can cause rice leaves to wilt and turn white, resulting in a 10-50% reduction in rice production in rice-growing countries every year. Wheat rust is an important disease that seriously affects wheat production safety worldwide. It includes leaf rust, stripe rust and stem rust. Its main characteristics are high frequency of occurrence, strong harm and wide range of impact. Once it occurs, it will cause huge losses to economic development. In epidemic years, it will cause a 10% to 30% reduction in wheat production, and in severe cases, it will be as high as 50% or more, or even a total crop failure. Therefore, it is urgent to create new, efficient, low-toxic and safe green pesticides to achieve lasting control of important plant diseases.
[0003] According to literature reports, in the past 30 years, target-based drug discovery (TDD) has been an important way to discover first-in-class drugs in the pharmaceutical industry. Major drug screening technologies such as high throughput screening (HTS) have also greatly accelerated the screening process of active molecules. Mitogen-activated protein kinase (MAPKK) is an important component of the eukaryotic kinase signaling pathway. It participates in the regulation of different developmental processes and the transduction of various extracellular signals, and plays a key role in regulating the life process of eukaryotic organisms.
[0004] Therefore, based on the candidate target proteins discovered in the early stage, synthetic screening of compounds that act on the target proteins and clarifying the structures of compounds with highly active bactericidal functions can provide an important scientific basis for the research and development and creation of new pesticides. Summary of the invention
[0005] The purpose of the present invention is to synthesize and screen compounds that act on target proteins of pathogens with clear functions through virtual screening, chemical synthesis, activity assays, and studies on the mechanism of action, so as to obtain compound structures with high activity and bactericidal functions.
[0006] In a first aspect, the present invention provides a plant disease control composition containing a tryptophan hydrazide or tryptophan amide compound, wherein the tryptophan hydrazide or tryptophan amide compound has a structure as shown in formula (I) and formula (II):
[0007]
[0008] in,
[0009] The oxygen ether bond is in one or more of the ortho, meta and para positions of the benzene ring;
[0010] R 1 One or more selected from deuterium, methyl, methoxy, trifluoromethyl, nitro, cyano, ethyl, vinyl, propenyl, halogen, allyl, methyl acyloxy, ethyl acyloxy, hydroxyl, amino and thiol;
[0011] R 2 One or more selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocycle.
[0012] Preferably,
[0013] The oxygen ether bonds are in the ortho, meta and para positions of the benzene ring;
[0014] R 1 One or more selected from deuterium, methyl, methoxy, trifluoromethyl, nitro, cyano, ethyl, vinyl, propenyl, halogen, allyl, methyl acyloxy, ethyl acyloxy, hydroxyl, amino and thiol;
[0015] R 2 One or more selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, and substituted or unsubstituted heterocycle.
[0016] Preferably,
[0017] R 1 Selected from C 1 -C 6 Alkyl, C 1 -C 6 Alkenyl, substituted or unsubstituted C 6 -C 15 Aryl, substituted or unsubstituted C 6 -C 10 One or more of the heterocyclic rings, wherein the substitution is by C 1 -C 6 The alkyl group may be substituted with phenyl, amino, nitro, cyano, difluoromethyl or trifluoromethyl.
[0018] Preferably,
[0019] R 2is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, propenyl, allyl, butenyl, pentenyl, hexenyl, methoxy, ethoxy, propoxy, butoxy, phenyl, chlorophenyl, bromophenyl, fluorophenyl, tolyl, aminophenyl, hydroxyphenyl, methoxyphenyl, trifluoromethylphenyl, benzyl, o-fluorobenzyl, m-fluorobenzyl, p-fluorobenzyl, o-bromobenzyl, m-bromobenzyl, p-bromobenzyl, o-chlorobenzyl, m-chlorobenzyl, p-chlorobenzyl, naphthalene phenyl, phenanthryl, pyridyl, 2-fluoropyridyl, 3-fluoropyridyl, 2-bromopyridyl, 3-bromopyridyl, 2-chloropyridyl, 3-chloropyridyl, 2-fluorothienyl, 3-fluorothienyl, 2-fluorofuranyl, 2-fluorotetrahydrofuranyl, 3-fluorofuranyl, 3-fluorotetrahydrofuranyl, 2-bromothienyl, 3-bromothienyl, 2-bromofuranyl, 3-bromofuranyl, 2-bromotetrahydrofuranyl, 3-bromotetrahydrofuranyl, 2-chlorothienyl, 3-chlorothienyl, p-cyanoanilino, p-hydroxyaniline 2-Chlorofuranyl, 3-Chlorofuranyl, 2-Chlorotetrahydrofuranyl, 3-Chlorotetrahydrofuranyl, o-hydroxybenzyl, m-hydroxybenzyl, p-hydroxybenzyl, o-aminobenzyl, m-aminobenzyl, p-aminobenzyl, o-methylbenzyl, m-methylbenzyl, p-methylbenzyl, 2-hydroxypyridine, 3-hydroxypyridyl, 4-hydroxypyridyl, 2-aminothienyl, 3-aminothienyl, 2-hydroxyfuranyl, 3-hydroxyfuranyl, 2-hydroxytetrahydrofuranyl, 3-hydroxytetrahydrofuranyl, 2-methylfuranyl One or more of 1-phenyl-3-trifluoromethyl-1H-pyrazolyl, 1-methyl-3-trifluoromethyl-1H-pyrazolyl, 1-methyl-3-difluoromethyl-1H-pyrazolyl, anilino and benzimidazolyl.
[0020] In the present invention, the tryptophan hydrazide or tryptophan amide compound is selected from one or more of the following compounds, as shown in Table 1.
[0021] Table 1 Types of tryptophan hydrazide or tryptophan amide compounds
[0022]
[0023] In a second aspect, a method for preparing the plant disease control composition of the present invention is provided, comprising the following steps:
[0024]
[0025] In a third aspect, a drug for controlling plant diseases is provided, wherein the drug comprises the plant disease control composition of the present invention.
[0026] Preferably, the plant disease is a plant fungal disease or a plant bacterial disease.
[0027] More preferably, the plant disease is wheat fusarium head blight, wheat stripe rust or wheat leaf blight.
[0028] Further preferably, the plant disease is one or more of wheat stripe rust, wheat head blight, potato late blight, blueberry root rot, pepper wilt, rapeseed sclerotinia, rapeseed anthracnose, rice sheath blight, rice bacterial leaf blight, tobacco bacterial wilt, citrus canker, kiwi canker, cucumber bacterial leaf blight, konjac bacterial leaf blight, grape canker, tomato canker and apple canker.
[0029] In the present invention, the dosage form of the agent is selected from emulsifiable concentrate (EC), dust (DP), wettable powder (WP), granule (GR), aqueous solution (AS), suspension (SC), ultra low volume spray (ULV), soluble powder (SP), microcapsule (MC), smoke concentrate (FU), emulsion in water (EW) or water dispersible granule (WG).
[0030] In a fourth aspect, a botanical agent is provided, comprising a safe and effective amount of the plant disease control composition according to the present invention.
[0031] In a fifth aspect, there is provided use of the plant disease control composition of the present invention in the preparation of an agent for plant disease control.
[0032] In a sixth aspect, there is provided the use of the plant disease control composition of the present invention in the preparation of a botanical agent.
[0033] In the present invention, "alkyl" includes branched and straight chain saturated hydrocarbon groups having a specific number of carbon atoms. 1-10 Alkyl" (or alkylene) is C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 and C 10 In addition, for example, "C 1-6Alkyl-means an alkyl group having 1 to 6 carbon atoms. The alkyl group may be unsubstituted or substituted so that one or more of its hydrogen atoms are replaced by other chemical groups. Alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (such as n-propyl and isopropyl), butyl (such as n-butyl, isobutyl, tert-butyl), pentyl (such as n-pentyl, isopentyl, neopentyl) and the like.
[0034] In the present invention, "alkenyl" refers to hydrocarbons including straight chain or branched structures, and having one or more carbon-carbon double bonds appearing at any stable point in the chain. 2-6 The term "alkenyl" (or "alkenylene") is intended to include C 2 , C 3 , C 4 , C 5 and C 6 Alkenyl. Examples of alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, 4-methyl-3-pentenyl, and the like.
[0035] In the present invention, "substituted" refers to any one or more hydrogen atoms on a designated atom or group being substituted with a selected designated group, provided that the general valence of the designated atom is not exceeded. If not otherwise specified, the substituent is named to the central structure. For example, it is understood that when (cycloalkyl) alkyl is a possible substituent, the point of attachment of the substituent to the central structure is in the alkyl portion. The ring double bond used herein is a double bond (such as C=C, C=N or N=N) formed between two adjacent ring atoms.
[0036] In the present invention, combinations of substituents and or variables are permitted only when these combinations produce stable compounds or useful synthetic intermediates. A stable compound or stable structure implies that the compound is sufficiently stable when isolated from a reaction mixture in a useful purity and then formulated to form an effective therapeutic agent. The compounds described herein do not currently contain N-halogens and sulfinic acid groups.
[0037] In the present invention, "cycloalkyl" refers to cycloalkyl groups, including mono-, bi- or polycyclic systems. 3-7 Cycloalkyl groups include C 3 , C 4 , C 5 , C 6 and C 7Cycloalkyl. Examples of cycloalkyl include, but are not limited to, cyclopropyl, butyl, cyclopentyl, cyclohexyl, norbornyl and the like. "Carbocycle" or "carbocycle residue" as used herein refers to any stable 3, 4, 5, 6 or 7-membered monocyclic or bicyclic or 7, 8, 9, 10, 11, 12 or 13-membered bicyclic or tricyclic rings, which may be saturated, partially unsaturated, unsaturated or aromatic. These carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, pentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadiene, bicyclooctane, bicyclononane, bicyclodecane, bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl and tetrahydronaphthyl (tetralin). Bridged rings are also included in the definition of carbocycle. If not otherwise stated, preferred carbocycles are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and phenyl. When the term "carbocycle" is used, it is intended to include "aryl". A bridged ring occurs when one or more carbon atoms connect two non-adjacent carbon atoms. Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a bicyclic ring. When a ring is bridged, the substituents of the ring are also present on the bridge.
[0038] In the present invention, "aryl group" refers to a monocyclic or bicyclic aromatic hydrocarbon group having 6 to 12 carbon atoms in the ring portion, such as phenyl and naphthyl, each of which may be substituted.
[0039] In the present invention, "halogen" or "halogen atom" refers to fluorine, chlorine, bromine and iodine.
[0040] In the present invention, "haloalkyl" refers to a substituted alkyl group having one or more halogen substituents. For example, "haloalkyl" includes mono-, di- and trifluoromethyl groups; even if the halo in the haloalkyl group is clearly defined as fluorine, chlorine, bromine or iodine, it also refers to a substituted alkyl group having one or more fluorine, chlorine, bromine or iodine substituents.
[0041] In the present invention, "heterocycle" refers to substituted and unsubstituted aromatic 5 or 6-membered monocyclic groups, 9- or 10-membered bicyclic groups, and 11 to 14-membered tricyclic groups, having at least one heteroatom (O, S or N) in at least one ring, and the heteroatom-containing ring preferably has 1, 2 or 3 heteroatoms selected from O, S and N. Each ring of the heteroatom-containing heterocyclic ring may contain one or two oxygen or sulfur atoms and / or from 1 to 4 nitrogen atoms, provided that the total number of heteroatoms in each ring is 4 or less and each ring has at least one carbon atom. The fused rings completing the bicyclic and tricyclic groups may contain only carbon atoms and may be saturated, partially saturated or unsaturated. The nitrogen and sulfur atoms may optionally be oxidized and the nitrogen atoms may optionally be quaternized. The bicyclic or tricyclic heteroaryl group must include at least one fully aromatic ring, and the nitrogen and other fused rings may be aromatic or non-aromatic. The heteroaryl group may be attached to any available nitrogen or carbon atom of any ring. If the other ring is a cycloalkyl or heterocycle, it is additionally optionally substituted with =0 (oxygen) when valence permits.
[0042] In the present invention, the monocyclic heteroaryl group includes pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, furanyl, thienyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl and the like.
[0043] In the present invention, the bicyclic heteroaryl group includes indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothienyl, quinolyl, tetrahydroisoquinolyl, isoquinolyl, benzimidazolyl, benzofuranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzofuranyl, cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridinyl, fluoropyridinyl, dihydroisoindolyl, tetrahydroquinolyl and the like.
[0044] If not otherwise specified, the compositions of the present invention are understood to include both the free form and its salts. "Salt" means acidic and / or basic salts formed with inorganic and / or organic acids and bases. In addition, "salt" may include zwitterions (inner salts), such as when the compounds of formula (I) and formula (II) contain basic fragments such as amines or pyridine or imidazole rings, and acidic fragments such as carboxylic acids. Pharmaceutically acceptable (i.e., non-toxic, physiologically acceptable) salts are preferred, such as acceptable metal and amine salts, in which the cation does not significantly contribute to the toxicity or biological activity of the salt. However, other salts may be useful, such as separation or purification steps used in the preparation process, and are therefore also included in the scope of the present invention. Salts of compounds of formula (I) and formula (II) can be formed by reacting the compounds of formula (I) and formula (II) with a certain amount of acid or base, such as an equal amount, in a medium such as an aqueous medium in which the salt can be precipitated or in which it is then lyophilized.
[0045] In the present invention, when it is mentioned that the substituent is alkenyl, alkynyl, alkyl, halogen, aryl, heteroaryl, alkoxy, cycloalkyl, hydroxyl, amino, mercapto, phosphino, or when these substituents are specifically alkenyl, alkynyl, alkyl, halogen, aryl, heteroaryl, alkoxy, cycloalkyl, hydroxyl, amino, mercapto, phosphino, it refers to one to three of the above substituents. For example, methylphenyl refers to phenyl substituted with one to three methyl groups.
[0046] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages:
[0047] The present invention is based on the action mechanism of the target protein, and through virtual screening, chemical synthesis, activity assay and action mechanism research, compounds that act on the target protein are synthesized and screened, thereby obtaining a compound structure with high activity bactericidal function.
[0048] In order to find active compounds with high bactericidal effects, the present invention uses PsFUZ7 as the target protein, conducts activity assays and mechanism of action studies through virtual screening and chemical synthesis, and synthesizes and screens compounds that act on the target protein to obtain a compound structure with high-activity bactericidal function.
[0049] The present invention synthesizes a series of tryptophan hydrazide or tryptophan amide compounds, and the tryptophan hydrazide or tryptophan amide compounds of the present invention are effective against eggplant Verticillium dahliae ( Verticillium dahliae )、Triticum streak rust( Puccinia striiformis f. sp. tritici )、Pepper wilt pathogen ( Fusariumoxysporum )、Sclerotinia sclerotiorum( Sclerotinia sclerotiorum )、Triticum fusarium ( Fusarium graminearum )、Botrytis cinerea( Botryosphaeria dothidea ), Blueberry root rot ( Pestalotiopsis clavispora )、Potato infestans ( Phytophthora infestans ) and Rhizoctonia solani ( Thanatephorus cucumeris ) and other pathogens, which can provide an important scientific basis for the research and development and creation of new pesticides. BRIEF DESCRIPTION OF THE DRAWINGS
[0050] In order to more clearly illustrate the technical solution of the present invention, the drawings involved in the description of the embodiments will be briefly introduced below. Obviously, the drawings in the description are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0051] Figure 1 1 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 1 in the example of the present invention.
[0052] Figure 2 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 1 in the example of the present invention.
[0053] Figure 3 : is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 2 in the example of the present invention.
[0054] Figure 4 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 2 in the example of the present invention.
[0055] Figure 5 3 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 3 in the examples of the present invention.
[0056] Figure 6 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 3 in the example of the present invention.
[0057] Figure 7 4 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 4 in the example of the present invention.
[0058] Figure 8 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 4 in the example of the present invention.
[0059] Fig. 9 5 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 5 in the examples of the present invention.
[0060] Fig.10 5 is the carbon nuclear magnetic resonance spectrum of the compound numbered 5 in the examples of the present invention.
[0061] Fig.11 : is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 6 in the example of the present invention.
[0062] Fig.12 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 6 in the example of the present invention.
[0063] Fig.13 : is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 7 in the example of the present invention.
[0064] Fig.14 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 7 in the example of the present invention.
[0065] Fig.15 7 is the nuclear magnetic resonance fluorine spectrum of the compound No. 7 in the example of the present invention.
[0066] Fig.16 8 is the hydrogen nuclear magnetic resonance spectrum of the compound No. 8 in the examples of the present invention.
[0067] Fig.17 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 8 in the example of the present invention.
[0068] Fig.18 8 is the nuclear magnetic resonance fluorine spectrum of the compound No. 8 in the examples of the present invention.
[0069] Fig.19 : is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 9 in the examples of the present invention.
[0070] Fig. 20 It is the carbon nuclear magnetic resonance spectrum of the compound numbered 9 in the examples of the present invention.
[0071] Fig.21 9 is the nuclear magnetic resonance fluorine spectrum of the compound No. 9 in the examples of the present invention.
[0072] Fig. 22 1 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 10 in the example of the present invention.
[0073] Fig.23 10 is the carbon nuclear magnetic resonance spectrum of the compound numbered 10 in the examples of the present invention.
[0074] Fig.24 1 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 11 in the example of the present invention.
[0075] Fig.25 1 is the carbon nuclear magnetic resonance spectrum of the compound numbered 11 in the examples of the present invention.
[0076] Fig.26 1 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 12 in the example of the present invention.
[0077] Fig. 27 1 is the carbon nuclear magnetic resonance spectrum of the compound numbered 12 in the examples of the present invention.
[0078] Fig.28 1 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 13 in the examples of the present invention.
[0079] Fig.29 13 is the carbon nuclear magnetic resonance spectrum of the compound numbered 13 in the examples of the present invention.
[0080] Fig.30 14 is the hydrogen nuclear magnetic resonance spectrum of the compound No. 14 in the example of the present invention.
[0081] Fig.31 14 is the carbon nuclear magnetic resonance spectrum of the compound numbered 14 in the examples of the present invention.
[0082] Fig.32 1 is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 15 in the example of the present invention.
[0083] Fig.3315 is the carbon nuclear magnetic resonance spectrum of the compound numbered 15 in the examples of the present invention.
[0084] Fig.34 15 is the nuclear magnetic resonance fluorine spectrum of the compound No. 15 in the example of the present invention.
[0085] Fig.35 1 is the hydrogen nuclear magnetic resonance spectrum of the compound No. 19 in the example of the present invention.
[0086] Fig.36 19 is the carbon nuclear magnetic resonance spectrum of the compound No. 19 in the examples of the present invention.
[0087] Fig.37 : is the hydrogen nuclear magnetic resonance spectrum of the compound numbered 20 in the examples of the present invention.
[0088] Fig.38 20 is the carbon nuclear magnetic resonance spectrum of the compound numbered 20 in the examples of the present invention.
[0089] Fig.39 21 is the hydrogen nuclear magnetic resonance spectrum of the compound No.
[0090] Fig.40 21 is the carbon nuclear magnetic resonance spectrum of the compound numbered 21 in the examples of the present invention.
[0091] Fig.41 22 is the hydrogen nuclear magnetic resonance spectrum of the compound No. 22 in the examples of the present invention.
[0092] Fig.42 22 is the carbon nuclear magnetic resonance spectrum of the compound numbered 22 in the examples of the present invention.
[0093] Fig.43 23 is the hydrogen nuclear magnetic resonance spectrum of the compound No. 23 in the examples of the present invention.
[0094] Fig.44 This is the carbon nuclear magnetic resonance spectrum of the compound numbered 23 in the examples of the present invention.
[0095] Fig.45 This is the nuclear magnetic resonance fluorine spectrum of the compound No. 23 in the examples of the present invention.
[0096] Fig.46 24 is the hydrogen nuclear magnetic resonance spectrum of the compound No. 24 in the examples of the present invention.
[0097] Fig.47 24 is the carbon nuclear magnetic resonance spectrum of the compound numbered 24 in the examples of the present invention. DETAILED DESCRIPTION
[0098] The technical scheme of the present invention is described below in conjunction with the examples, but the present invention is not limited to the following examples. The experimental methods and detection methods described in each example are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.
[0099] Example 1: Preparation of ethyl 4-formylphenoxyacetate
[0100] 1 g (8.19 mmol) of p-hydroxybenzaldehyde was added to a 150 mL round-bottom flask, and then 1.09 mL (9.83 mmol) of ethyl bromoacetate and 60 mL of tetrahydrofuran were added, and the temperature was raised to 60 °C for about 12 h. The reaction progress was monitored by TLC. When the reaction was basically completed, the reaction was stopped. The tetrahydrofuran was removed by vacuum distillation. 100 mL of EA was dissolved in the system, and the system was washed three times with 50 mL of water. Anhydrous sodium sulfate was added to the organic phase for drying, suction filtration, and vacuum distillation was performed to remove the solvent. The product was obtained by column chromatography (PE / EA=20 / 1). The product was 1.5 g of white oil with a yield of 87.9%.
[0101] Example 2: Preparation of ethyl 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetate
[0102] Take 1.5 g (7.2 mmol) of ethyl 4-formylphenoxyacetate and add it to a 100 mL round-bottom flask, add 1.2 times the amount of tryptamine, and use 40 mL of methanol as the solvent. React for about 5 h, then add 2 times the amount of sodium borohydride. After 12 h, monitor the reaction progress by TLC. When the reaction is complete, stop the reaction; remove the solvent by vacuum distillation, dissolve the system in 100 mL EA, wash with 50 mL water 3 times, add anhydrous sodium sulfate to the organic phase for drying, filter, vacuum distill and desolventize, and obtain the product by column chromatography (PE / EA=1 / 2), 1.65 g of yellow oil, with a yield of 64.9%.
[0103] Example 3: Preparation of 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid
[0104] Take 1.6 g (4.54 mmol) of ethyl 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid and add it to a 100 mL round-bottom flask. Add 2 times the amount of sodium hydroxide and use 40 mL of methanol as the solvent. The reaction was carried out for about 5 h. The reaction progress was monitored by TLC. When the reaction was completed, the reaction was stopped. The solvent methanol was removed by vacuum distillation. Concentrated hydrochloric acid was added to the system. The pH was adjusted to 2-3. The system was filtered and washed with ice water 3 times (5 mL×3). The filter cake was dried under an infrared lamp to obtain 1.4 g of a white solid with a yield of 91.3%.
[0105] Example 4: Preparation of 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)-n''-phenylacetohydrazide
[0106] 0.1 g (0.31 mmol) of 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid was added to a 15 mL pressure bottle, and then 0.082 g (0.46 mmol) of EDCI, 0.037 g (0.31 mmol) of DMAP, and 3 mL of DMF were added to dissolve the system. Finally, 0.04 g (0.37 mmol) of phenylhydrazine was added and stirred at room temperature for about 5 h. The reaction progress was monitored by TLC. After the reaction was completed, the reaction was stopped. The compound in the EA dissolution system was dissolved in 150 mL of EA, and washed three times with 50 mL of water. The organic phase was dried with anhydrous sodium sulfate, filtered, and desolventized by reduced pressure distillation to obtain a light yellow solid. Anhydrous ethanol was added for recrystallization to precipitate a light yellow solid, which was filtered and washed with a small amount of anhydrous ethanol. The compound was placed under an infrared lamp and dried and weighed to obtain 0.047 g, with a yield of 33.6%.
[0107] Example 5: Preparation of 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)-n''-phenylacetamide
[0108] 0.1 g (0.31 mmol) of 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid was added to a 15 mL pressure bottle, and then 0.082 g (0.46 mmol) of EDCI, 0.037 g (0.31 mmol) of DMAP, and 3 mL of DMF were added to dissolve the system. Finally, 0.04 g (0.37 mmol) of aniline was added and stirred at room temperature for about 5 h. The reaction progress was monitored by TLC. After the reaction was completed, the reaction was stopped. The compound in the 150 mL EA dissolution system was washed three times with 50 mL of water. The organic phase was dried with anhydrous sodium sulfate, filtered, and desolvated under reduced pressure to obtain a yellow solid. Anhydrous ethanol was added for recrystallization to precipitate a yellow solid, which was filtered and washed with a small amount of anhydrous ethanol. The compound was placed under an infrared lamp and dried and weighed to obtain 0.057 g, with a yield of 43.6%.
[0109] Example 6: Preparation of ethyl 2-(4-((2-(3-(4-chloroindolyl)ethyl)amino)methyl)phenoxy)acetate
[0110] Take 1.5 g (7.2 mmol) of ethyl 4-formylphenoxyacetate and add it to a 100 mL round-bottom flask, add 1.2 times the amount of 4-chloro-tryptamine, and use 40 mL of methanol as the solvent. React for about 5 h, then add 2 times the amount of sodium borohydride, monitor the reaction progress by TLC after 12 h, and stop the reaction after the reaction is complete; remove the solvent by vacuum distillation, dissolve the system in 100 mL EA, wash with 50 mL water 3 times, add anhydrous sodium sulfate to the organic phase for drying, filter, vacuum distill and desolventize, and obtain the product by column chromatography (PE / EA=1 / 2), 1.75 g of yellow oil, with a yield of 69.9%.
[0111] Example 7: Preparation of 2-(4-((2-(3-4-chloroindolyl)ethyl)amino)methyl)phenoxy)acetic acid
[0112] Take 1.6 g (4.54 mmol) of ethyl 2-(4-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid and add it to a 100 mL round-bottom flask, add 2 times the amount of sodium hydroxide, and use 40 mL of methanol as the solvent. The reaction was carried out for about 5 h, and the reaction progress was monitored by TLC. When the reaction was completed, the reaction was stopped; the solvent methanol was removed by vacuum distillation, concentrated hydrochloric acid was added to the system, the pH was adjusted to 2-3, filtered, and washed with ice water 3 times (5 mL×3). The filter cake was placed under an infrared lamp to dry to obtain 1.5 g of a white solid with a yield of 93.3%.
[0113] Example 8: Preparation of 2-(4-((2-(3-4-chloroindolyl))ethyl)amino)methyl)phenoxy)-n''-phenylacetohydrazide
[0114] 0.1 g (0.31 mmol) of 2-(4-((2-(3-4-chloroindolyl))ethyl)amino)methyl)phenoxy)acetic acid was added to a 15 mL pressure bottle, and then 0.082 g (0.46 mmol) of EDCI, 0.037 g (0.31 mmol) of DMAP, and 3 mL of DMF were added to dissolve the system. Finally, 0.04 g (0.37 mmol) of phenylhydrazine was added and stirred at room temperature for about 5 h. The reaction progress was monitored by TLC. After the reaction was completed, the reaction was stopped. The compound in the EA dissolution system was dissolved in 150 mL of EA, and washed three times with 50 mL of water. The organic phase was dried with anhydrous sodium sulfate, filtered, and desolvated under reduced pressure to obtain a light yellow solid. Anhydrous ethanol was added for recrystallization to precipitate a light yellow solid, which was filtered and washed with a small amount of anhydrous ethanol. The compound was placed under an infrared lamp and dried and weighed to obtain 0.047 g, with a yield of 33.6%.
[0115] Example 9: Preparation of ethyl 3-formylphenoxyacetate
[0116] 1 g (8.19 mmol) of m-hydroxybenzaldehyde was added to a 150 mL round-bottom flask, and then 1.09 mL (9.83 mmol) of ethyl bromoacetate and 60 mL of tetrahydrofuran were added. The temperature was raised to 60 °C and the reaction was reacted for about 12 h. The reaction progress was monitored by TLC. The reaction was basically completed and the reaction was stopped. The tetrahydrofuran was removed by vacuum distillation. 100 mL of EA was dissolved in the system and the system was washed three times with 50 mL of water. Anhydrous sodium sulfate was added to the organic phase for drying, suction filtration, and vacuum distillation was performed to remove the solvent. The product was obtained by column chromatography (PE / EA=20 / 1). The product was 1.4 g of white oil with a yield of 83.9%.
[0117] Example 10: Preparation of ethyl 2-(3-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetate
[0118] Take 1.5 g (7.2 mmol) of ethyl 3-formylphenoxyacetate and add it to a 100 mL round-bottom flask, add 1.2 times the amount of tryptamine, and use 40 mL of methanol as the solvent. React for about 5 h, then add 2 times the amount of sodium borohydride, monitor the reaction progress by TLC after 12 h, and stop the reaction after the reaction is complete; remove the solvent by vacuum distillation, dissolve the system in 100 mL EA, wash with 50 mL water 3 times, add anhydrous sodium sulfate to the organic phase for drying, filter, vacuum distill and desolventize, and obtain the product by column chromatography (PE / EA=1 / 2), 1.35 g of yellow oil, with a yield of 61.9%.
[0119] Example 11: Preparation of 2-(3-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid
[0120] Take 1.6 g (4.54 mmol) of ethyl 2-(3-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid and add it to a 100 mL round-bottom flask, add 2 times the amount of sodium hydroxide, and use 40 mL of methanol as the solvent. The reaction was carried out for about 5 h, and the reaction progress was monitored by TLC. When the reaction was completed, the reaction was stopped; the solvent methanol was removed by vacuum distillation, concentrated hydrochloric acid was added to the system, the pH was adjusted to 2-3, filtered, washed with ice water 3 times (5 mL×3), and the filter cake was dried under an infrared lamp to obtain 1.3 g of white solid with a yield of 81.3%.
[0121] Example 12: Preparation of 2-(3-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)-n''-phenylacetohydrazide
[0122] 0.1 g (0.31 mmol) of 2-(3-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid was added to a 15 mL pressure bottle, and then 0.082 g (0.46 mmol) of EDCI, 0.037 g (0.31 mmol) of DMAP, and 3 mL of DMF were added to dissolve the system. Finally, 0.04 g (0.37 mmol) of phenylhydrazine was added and stirred at room temperature for about 5 h. The reaction progress was monitored by TLC. After the reaction was completed, the reaction was stopped. The compound in the EA dissolution system was dissolved in 150 mL of EA, and washed three times with 50 mL of water. The organic phase was dried with anhydrous sodium sulfate, filtered, and desolvated under reduced pressure to obtain a light yellow solid. Anhydrous ethanol was added for recrystallization to precipitate a light yellow solid, which was filtered and washed with a small amount of anhydrous ethanol. The compound was placed under an infrared lamp and dried and weighed to obtain 0.057 g, with a yield of 39.6%.
[0123] Example 13: Preparation of ethyl 2-formylphenoxyacetate
[0124] 1 g (8.19 mmol) of salicylaldehyde was added to a 150 mL round-bottom flask, and then 1.09 mL (9.83 mmol) of ethyl bromoacetate and 60 mL of tetrahydrofuran were added. The temperature was raised to 60 °C and the reaction was reacted for about 12 h. The reaction progress was monitored by TLC. The reaction was basically completed and the reaction was stopped. The tetrahydrofuran was removed by vacuum distillation. 100 mL of EA was dissolved in the system and washed three times with 50 mL of water. Anhydrous sodium sulfate was added to the organic phase for drying, suction filtration, and vacuum distillation was performed to remove the solvent. The product was obtained by column chromatography (PE / EA=20 / 1). The white oil was 1.6 g with a yield of 88.9%.
[0125] Example 14: Preparation of ethyl 2-(2-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetate
[0126] Take 1.5 g (7.2 mmol) of ethyl 2-formylphenoxyacetate and add it to a 100 mL round-bottom flask, add 1.2 times the amount of tryptamine, and use 40 mL of methanol as the solvent. React for about 5 h, then add 2 times the amount of sodium borohydride, monitor the reaction progress by TLC after 12 h, and stop the reaction after the reaction is complete; remove the solvent by vacuum distillation, dissolve the system in 100 mL EA, wash with 50 mL water 3 times, add anhydrous sodium sulfate to the organic phase for drying, filter, vacuum distill and desolventize, and obtain the product by column chromatography (PE / EA=1 / 2), 1.35 g of yellow oil, with a yield of 61.9%.
[0127] Example 15: Preparation of 2-(2-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid
[0128] Take 1.6 g (4.54 mmol) of ethyl 2-(2-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid and add it to a 100 mL round-bottom flask, add 2 times the amount of sodium hydroxide, and use 40 mL of methanol as the solvent. The reaction was carried out for about 5 h, and the reaction progress was monitored by TLC. When the reaction was completed, the reaction was stopped; the solvent methanol was removed by vacuum distillation, concentrated hydrochloric acid was added to the system, the pH was adjusted to 2-3, filtered, washed with ice water 3 times (5 mL×3), and the filter cake was dried under an infrared lamp to obtain 1.4 g of white solid with a yield of 85.3%.
[0129] Example 16: Preparation of 2-(2-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)-n''-phenylacetohydrazide
[0130] 0.1 g (0.31 mmol) of 2-(2-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)acetic acid was added to a 15 mL pressure bottle, and then 0.082 g (0.46 mmol) of EDCI, 0.037 g (0.31 mmol) of DMAP, and 3 mL of DMF were added to dissolve the system. Finally, 0.04 g (0.37 mmol) of phenylhydrazine was added and stirred at room temperature for about 5 h. The reaction progress was monitored by TLC. After the reaction was completed, the reaction was stopped. The compound in the EA dissolution system was dissolved in 150 mL of EA, and washed three times with 50 mL of water. The organic phase was dried with anhydrous sodium sulfate, filtered, and desolventized by reduced pressure distillation to obtain a light yellow solid. Anhydrous ethanol was added for recrystallization to precipitate a light yellow solid, which was filtered and washed with a small amount of anhydrous ethanol. The compound was placed under an infrared lamp and dried and weighed to obtain 0.051 g, with a yield of 35.6%.
[0131] It should be noted that all tryptophan hydrazides or tryptophan amides in the present invention can be synthesized according to the above method, and the substituents on the aromatic rings do not affect the synthesis steps.
[0132] The structures and H NMR and C NMR data of some tryptophan hydrazides or tryptophan amides synthesized in the examples of the present invention are shown in Table 2, and the physicochemical properties are shown in Table 3. Among them, the tryptophan hydrazides or tryptophan amides compounds numbered 1-24 in Table 1 are the same as the tryptophan hydrazides or tryptophan amides compounds numbered 1-24 in Table 2. The tryptophan hydrazides or tryptophan amides compounds numbered 1-24 in Table 2 are the same as the tryptophan hydrazides or tryptophan amides compounds numbered 1-24 in Table 3.
[0133] Table 2 H NMR, C NMR and F NMR data of some tryptophan hydrazide or tryptophan amide compounds
[0134]
[0135] Table 3 Physicochemical properties of some tryptophan hydrazides or tryptophan amides
[0136]
[0137] The hydrogen spectrum result of the compound numbered 1 [(2-(3-((2-(3-indolyl)ethyl)amino)methyl)phenoxy)-n''-phenylacetohydrazide)] in the embodiment of the present invention is as follows: Figure 1 As shown, the carbon spectrum results of the compound numbered 1 in the embodiment of the present invention are as follows Figure 2 As shown, Figure 1 and Figure 2 The hydrogen spectrum and carbon spectrum of compound 1 shown here fully confirm its chemical structure. The results of hydrogen nuclear magnetic resonance spectrum of compound numbered 2 in the example of the present invention are as follows: Figure 3 As shown, the carbon NMR spectrum results of the compound numbered 2 in the embodiment of the present invention are as follows Figure 4 The results of the H NMR spectrum of the compound No. 3 in the embodiment of the present invention are as shown in Figure 5 As shown, the carbon NMR spectrum results of the compound numbered 3 in the embodiment of the present invention are as follows Figure 6 The results of the H NMR spectrum of the compound No. 4 in the embodiment of the present invention are as shown in Figure 7 As shown, the carbon NMR spectrum results of the compound numbered 4 in the embodiment of the present invention are as follows Figure 8 The results of the H NMR spectrum of the compound No. 5 in the embodiment of the present invention are shown in Fig. 9 As shown, the carbon NMR spectrum results of the compound numbered 5 in the embodiment of the present invention are as follows Fig.10 The results of the H NMR spectrum of the compound No. 6 in the embodiment of the present invention are shown in Fig.11 As shown, the carbon NMR spectrum results of the compound numbered 6 in the embodiment of the present invention are as follows Fig.12The results of the H NMR spectrum of the compound No. 7 in the embodiment of the present invention are as shown in Fig.13 As shown, the carbon NMR spectrum results of the compound numbered 7 in the embodiment of the present invention are as follows Fig.14 The results of the nuclear magnetic resonance fluorine spectrum of the compound numbered 7 in the embodiment of the present invention are as shown in Fig.15 As shown, the nuclear magnetic resonance hydrogen spectrum results of the compound numbered 8 in the embodiment of the present invention are as follows Fig.16 As shown, the carbon NMR spectrum results of the compound No. 8 in the embodiment of the present invention are as follows Fig.17 As shown; the NMR fluorine spectrum results of the compound No. 8 in the embodiment of the present invention are as follows Fig.18 As shown, the nuclear magnetic resonance hydrogen spectrum result of the compound numbered 9 in the embodiment of the present invention is as follows Fig.19 As shown, the carbon NMR spectrum results of the compound numbered 9 in the embodiment of the present invention are as follows Fig. 20 As shown, the NMR fluorine spectrum results of the compound No. 9 in the embodiment of the present invention are as follows Fig.21 The results of the H NMR spectrum of the compound No. 10 in the embodiment of the present invention are as shown in Fig. 22 As shown, the carbon NMR spectrum results of the compound numbered 10 in the embodiment of the present invention are as follows Fig.23 As shown, the nuclear magnetic resonance hydrogen spectrum result of the compound numbered 11 in the embodiment of the present invention is as follows Fig.24 As shown, the carbon NMR spectrum results of the compound numbered 11 in the embodiment of the present invention are as follows Fig.25 The results of the H NMR spectrum of the compound No. 12 in the embodiment of the present invention are as shown in Fig.26 As shown, the carbon NMR spectrum results of the compound numbered 12 in the embodiment of the present invention are as follows Fig. 27 The results of the H NMR spectrum of the compound No. 13 in the embodiment of the present invention are as shown in Fig.28 As shown, the carbon NMR spectrum results of the compound numbered 13 in the embodiment of the present invention are as follows Fig.29 The results of the H NMR spectrum of the compound No. 14 in the embodiment of the present invention are as shown in Fig.30 As shown, the carbon NMR spectrum results of the compound numbered 14 in the embodiment of the present invention are as follows Fig.31 The results of the H NMR spectrum of the compound No. 15 in the embodiment of the present invention are as shown in Fig.32 As shown, the carbon NMR spectrum results of the compound numbered 15 in the embodiment of the present invention are as follows Fig.33 As shown, the NMR fluorine spectrum results of the compound No. 15 in the embodiment of the present invention are as follows Fig.34 The results of the H NMR spectrum of the compound No. 19 in the embodiment of the present invention are as shown in Fig.35 As shown, the carbon NMR spectrum results of the compound No. 19 in the embodiment of the present invention are as follows Fig.36As shown; Fig.37 The nuclear magnetic resonance hydrogen spectrum result of the compound numbered 20 in the embodiment of the present invention is as follows Fig.37 As shown, the carbon NMR spectrum results of the compound numbered 20 in the embodiment of the present invention are as follows Fig.38 The results of the H NMR spectrum of the compound No. 21 in the embodiment of the present invention are as shown in Fig.39 As shown, the carbon NMR spectrum results of the compound numbered 21 in the embodiment of the present invention are as follows Fig.40 The results of the H NMR spectrum of the compound No. 22 in the embodiment of the present invention are as shown in Fig.41 As shown, the carbon NMR spectrum results of the compound numbered 22 in the embodiment of the present invention are as follows Fig.42 The results of the H NMR spectrum of the compound No. 23 in the embodiment of the present invention are as shown in Fig.43 As shown, the carbon NMR spectrum results of the compound numbered 23 in the embodiment of the present invention are as follows Fig.44 As shown, the NMR fluorine spectrum results of the compound No. 23 in the embodiment of the present invention are as follows Fig.45 The results of the H NMR spectrum of the compound No. 24 in the embodiment of the present invention are as shown in Fig.46 As shown, the carbon NMR spectrum results of the compound numbered 24 in the embodiment of the present invention are as follows Fig.47 The hydrogen spectrum, carbon spectrum and fluorine spectrum of each compound shown in each figure of the present invention can fully confirm its chemical structure.
[0138] Effect verification
[0139] Experiment 1
[0140] The antibacterial activity of the compounds numbered 1-24 against plant pathogenic fungi such as wheat stripe rust was determined on wheat plants using the pot protection method. All strains were fresh and vigorous. The compounds to be tested were weighed with a 1 / 10,000 balance and added to DMSO for dissolution. The drug solution was added with 5 mL of Tween-20, mixed and evenly sprayed on a wheat pot with one leaf and one heart. After 24 hours, the leaves were inoculated with bacteria, kept moist in the dark for 24 hours, and cultured in a greenhouse. After 14 days, the data was recorded when the disease index of the blank group was greater than 80, and triadimefon was used as a positive control. In the early stage, we selected 200 μg / mL as the initial screening concentration. When the corresponding inhibition rate of the compound at this concentration was greater than 50%, a low concentration test was performed on it. The leaves after the disease of each treatment were graded and investigated. The grading method is as follows:
[0141] Level 0: no lesions;
[0142] Level 1: The lesion area accounts for less than 5% of the entire leaf area;
[0143] Level 3: The lesion area accounts for 6% to 10% of the entire leaf area;
[0144] Level 5: The lesion area accounts for 11% to 25% of the entire leaf area;
[0145] Level 7: The lesion area accounts for 26% to 50% of the entire leaf area;
[0146] Level 9: The lesion area accounts for more than 50% of the total leaf area.
[0147] The survey results were statistically analyzed to calculate the disease index and control effect of each treatment with different concentrations. The disease index was calculated according to formula (1):
[0148] Disease index = ∑(number of cases at each level × representative value at each level) / (total number of leaves surveyed × highest value) × 100
[0149] Control effect = (disease control index - disease protection index) / disease control index × 100%
[0150] The embodiments of the present invention are used to illustrate the technical scheme of the present invention, but the contents of the embodiments are not limited thereto. The experimental results of some of the above target compounds are shown in Tables 4 and 5. Among them, the tryptophan hydrazide or tryptophan amide compounds numbered 1-24 in Table 4 are the same as the tryptophan hydrazide or tryptophan amide compounds numbered 1-24 in Table 3.
[0151] Table 4 Control activity of tryptophan hydrazide or tryptophan amide compounds against wheat stripe rust
[0152]
[0153] As can be seen from Table 4, the compounds numbered 1-24 were tested for biological activity using the potted protection method, with triadimefon as the control agent and wheat stripe rust as the test object. The test results show that this series of compounds has good anti-stripe rust activity. Most of the compounds have good anti-stripe rust activity at 200 ppm and 100 ppm, and are better than the control agents azoxystrobin and kresoxim-methyl. Among them, the compounds numbered 5 and 6 have high control activity against wheat stripe rust, with protection rates of 50% and 60% at 25 ppm, respectively, close to the control agent triadimefon 64.3%, and much higher than the control agents azoxystrobin (48.6%; 100 ppm) and kresoxim-methyl (45.2%; 100 ppm).
[0154] Table 5 EC values of some compounds containing tryptophan hydrazides or tryptophan amides for control of wheat stripe rust 50
[0155]
[0156] The compounds in Table 4 whose antibacterial activity was still greater than 50% at 25 ppm were subjected to half-inhibitory activity concentration (EC 50 ) test, it can be seen from Table 5 that the compounds No. 5 and No. 6 have good control activity, and the EC 50 The values were 23.68 and 19.77 μg / mL, respectively, and can be used to prepare pesticides against plant pathogenic fungi.
[0157] Experiment 2
[0158] The inhibition rate of some of the compounds numbered 1-24 on plant pathogens was tested by turbidity method, and the test object was rice bacterial leaf blight pathogen. DMSO was dissolved in the culture medium as a blank control. Rice bacterial leaf blight pathogen (rice bacterial leaf blight pathogen in M210 solid culture medium) was placed in NB culture medium, and cultured in a constant temperature shaker at 28°C and 180rpm until the logarithmic growth phase for use; the agent (compound) was prepared into 5mL of toxic NB liquid culture medium with different concentrations (for example: 25, 12.5μg / mL) and added to the test tube, and 40μL of NB liquid culture medium containing plant pathogenic bacteria was added respectively, and the mixture was shaken in a constant temperature shaker at 28-30°C and 180rpm, and the rice bacterial leaf blight pathogen was cultured for 36h. The OD of the bacterial solution of each concentration was measured on a spectrophotometer. 595 The OD of the corresponding concentration of toxic sterile NB liquid culture medium was also measured. 595 value.
[0159] Corrected OD value = OD value of bacterial culture medium - OD value of sterile culture medium
[0160] Inhibition rate % = [(corrected control culture medium bacterial solution OD value - corrected toxic culture medium OD value) / corrected control culture medium bacterial solution OD value] × 100
[0161] The embodiments of the present invention are used to illustrate the technical solutions of the present invention, but the contents of the embodiments are not limited thereto. The experimental results are shown in Tables 6 and 7. Among them, the tryptophan hydrazide or tryptophan amide compounds numbered 1-12 in Table 6 are the same as the tryptophan hydrazide or tryptophan amide compounds with the same number in Table 3. The tryptophan hydrazide or tryptophan amide compounds numbered 3, 6, 10, 12, 18, 22 and 24 in Table 7 are the same as the tryptophan hydrazide or tryptophan amide compounds with the same number in Table 3.
[0162] Table 6 Inhibitory activity of tryptophan hydrazide or tryptophan amide compounds against Xanthomonas oryzae
[0163]
[0164] Table 7 EC values of tryptophan hydrazide or tryptophan amide compounds against rice pathogenic bacteria 50
[0165]
[0166] The compounds in Table 6 that were still more than 50% active at 12.5 ppm were subjected to the half-inhibitory concentration (EC 50 ) test, it can be seen from Table 6 and Table 7 that in the in vitro test, the target compounds showed good inhibitory activity against plant pathogenic bacteria. Among them, the compounds numbered 3, 6, 10, 12, 18, 22, and 24 have good anti-rice bacterial blight activity, which is much better than the control agents chlorothalonil and thiophanate-methyl, and can be used to prepare pesticides against plant pathogenic bacteria.
[0167] Experiment 3
[0168] The mycelial growth rate inhibition method was used to determine the effects of the compounds on Fusarium graminearum ( Fusarium graminearum ), Fusarium wilt of pepper ( Fusarium oxysporum ), Sclerotinia sclerotiorum ( Sclerotinia sclerotiorum ), Colletotrichum rapae Colletotrichun higginsianum ), blueberry root rot pathogen ( Phytophthora cinnamomi ) and Botrytis cinerea ( Botryosphaeria dothidea ) and other plant pathogenic fungi and oomycetes, and the strains were activated in advance. Use a 1 / 10,000 balance to weigh the compound to be tested, add 1 mL of DMSO to dissolve it, and then transfer it to a 15 mL sterilized centrifuge tube on a sterile operating table. Add 9 mL of Tween-20 to make 10 mL, pour it into the culture medium, mix it well, and evenly distribute it to 9 culture dishes for cooling and standby use; in a sterile operating table, use a sterile puncher (5 mm) to make a bacterial cake from the normally growing colonies, and use a bacterial ring to turn the bacterial cake upside down in the center of the culture medium, and culture it at 28°C for 3 to 5 days. When the control colony grows to 2 / 3 of the diameter of the entire plate, use a ruler to measure it twice using the cross method, and calculate the colony diameter size with the average value. In the early stage, we selected 25 μg / mL as the initial screening concentration. When the compound has an inhibition rate of more than 50% on the corresponding pathogen at this concentration, EC 50 Test, the mycelial growth inhibition rate is calculated according to the following formula. Oxymethol and boscalid are used as control agents in the test. The calculation formula is as follows: Inhibition rate (%) = (C1-C2) / (C1-0.4)×100 In the formula:
[0169] C1—control colony diameter, i.e., DMSO-treated colony diameter;
[0170] C2—treated colony diameter, i.e., the diameter of the colony treated with the drug;
[0171] 0.4—is the diameter of the mother mushroom cake.
[0172] The embodiments of the present invention are used to illustrate the technical solutions of the present invention, but the contents of the embodiments are not limited thereto. The experimental results are shown in Tables 8 and 9. Among them, the tryptophan hydrazide or tryptophan amide compounds numbered 1-24 in Table 8 are the same as the tryptophan hydrazide or tryptophan amide compounds numbered 1-24 in Table 3. Among them, the tryptophan hydrazide or tryptophan amide compounds numbered 1-24 in Table 9 are the same as the tryptophan hydrazide or tryptophan amide compounds numbered 1-24 in Table 3.
[0173] Table 8 Inhibitory activity of compounds containing tryptophan hydrazides or tryptophan amides against plant pathogenic fungi
[0174]
[0175] As can be seen from Table 8, in the in vitro test, the target compounds showed good inhibitory activity against plant pathogenic bacteria. Among them, most of the compounds had high antibacterial activity against wheat fusarium, with inhibition rates ranging from 59.7% to 96.0%, which was better than the control agents oxadipamide and boscalid; the compounds numbered 7, 14, 16, 17, 19, 22, and 23 had high anti-pepper wilt activity, with inhibition rates of 100%, 97.9%, 98.7%, 100%, 100%, 98.7%, and 100%, respectively, which was better than the control drugs oxadipamide and boscalid; the compounds numbered 10 and 17 had high anti-Botrytis cinerea activity, with inhibition rates of 100%, 97.9%, 98.7%, 100%, 100%, 98.7%, and 100%, respectively. The inhibition rates of the compounds No. 2, 5, 7 and 17 against rapeseed sclerotinia were 100%, 100%, 95.8% and 98.6%, respectively; the inhibition rates of the compounds No. 2, 5, 7 and 10 against rapeseed anthracnose were all 100%; the compounds No. 7, 10 and 14 had good anti-blueberry root rot activity, with inhibition rates of 90.2%, 90.5% and 92.3%, respectively, which were better than the control drugs No. 2, 5, 7 and 17. In addition, the other compounds had high antifungal activity and could be used to prepare pesticides against plant pathogenic fungi.
[0176] Table 9 EC values of tryptophan hydrazide or tryptophan amide compounds against plant pathogenic fungi 50
[0177]
[0178] The compounds in Table 8 that were still more than 50% active at 25 ppm were subjected to the half-inhibitory activity concentration (EC 50) test, it can be seen from Table 9 that in the in vitro test, the target compounds showed good inhibitory activity against plant pathogenic bacteria. Among them, the compounds numbered 2, 5, 7, 10, and 17 have good antibacterial activity, which is much higher than the control drug, and can be used to prepare pesticides against plant pathogenic fungi.
[0179] It should be understood that the disclosed invention is not limited only to the specific method, scheme and material of description, because these all can change.It should also be understood that the terminology used herein is only for the purpose of describing specific embodiment scheme, rather than being intended to limit the scope of the present invention, and the scope of the present invention is only limited to the appended claims.
[0180] Those skilled in the art will also recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are also intended to be encompassed by the appended claims.
Claims
1. A plant disease control composition containing tryptophan hydrazide or tryptophan amide compounds, wherein The characteristic is that The tryptophan hydrazide compound has a structure as shown in formula (II): , The tryptamine amide compound has a structure as shown in formula (I): , in, The oxygen ether bond is in the ortho, meta or para position of the benzene ring; R 1 One or more selected from methyl, methoxy, trifluoromethyl, ethyl and halogen; R 2 One or more selected from phenyl, chlorophenyl, bromophenyl, fluorophenyl, tolyl, aminophenyl, hydroxyphenyl, methoxyphenyl and trifluoromethylphenyl.
2. The method for preparing the plant disease control composition according to claim 1, characterized in that: The following steps are involved: 。 3. A medicament for preventing and controlling plant diseases, characterized in that: The agent comprises the plant disease control composition according to claim 1.
4. A herbal medicine, characterized in that: The invention comprises a safe and effective amount of the plant disease control composition according to claim 1.
